These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1513579)

  • 1. Treatment of postcataract fibrinous membranes with tissue plasminogen activator.
    Moon J; Chung S; Myong Y; Chung S; Park C; Baek N; Rhee S
    Ophthalmology; 1992 Aug; 99(8):1256-9. PubMed ID: 1513579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.
    Wedrich A; Menapace R; Mühlbauer-Ries E
    Int Ophthalmol; 1994-1995; 18(5):277-80. PubMed ID: 7607808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J; Marek J; Zajac-Pytrus H; Nizankowska MH; Koziorowska M
    Klin Oczna; 1996; 98(6):423-5. PubMed ID: 9340414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes.
    Starck T; Hopp L; Held KS; Marouf LM; Yee RW
    J Cataract Refract Surg; 1995 Mar; 21(2):219-24. PubMed ID: 7791066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K; Greite JH; Bartenschlager EM
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
    Erol N; Ozer A; Topbas S; Yildirim N; Yurdakul S
    Ophthalmic Surg Lasers Imaging; 2003; 34(6):451-6. PubMed ID: 14620747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
    Wedrich A; Menapace R; Ries E; Polzer I
    J Cataract Refract Surg; 1997; 23(6):873-7. PubMed ID: 9292671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracameral r-tPA for the management of severe fibrinous reactions in TASS after cataract surgery.
    Osaadon P; Belfair N; Lavy I; Walter E; Levy J; Tuuminen R; Achiron A; Knyazer B
    Eur J Ophthalmol; 2022 Jan; 32(1):200-204. PubMed ID: 33719630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations].
    Heiligenhaus A; Schilling H; Schilling M; Mellin KB
    Ophthalmologe; 1996 Feb; 93(1):49-53. PubMed ID: 8867161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of anterior chamber fibrin following cataract surgery with tissue plasminogen activator.
    Lesser GR; Osher RH; Whipple D; Abrams GW; Cionni RJ
    J Cataract Refract Surg; 1993 Mar; 19(2):301-5. PubMed ID: 8487179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children.
    Klais CM; Hattenbach LO; Steinkamp GW; Zubcov AA; Kohnen T
    J Cataract Refract Surg; 1999 Mar; 25(3):357-62. PubMed ID: 10079440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye].
    Rehfeldt K; Höh H
    Ophthalmologe; 1999 Sep; 96(9):587-93. PubMed ID: 10501987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
    Williams GA; Lambrou FH; Jaffe GA; Snyder RW; Green GD; Devenyi RG; Abrams GW
    Arch Ophthalmol; 1988 Aug; 106(8):1055-8. PubMed ID: 3135790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation.
    Tan DT; Chee SP; Lim L; Lim AS
    Ophthalmology; 1999 Feb; 106(2):223-31. PubMed ID: 9951469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.
    Dotan A; Kaiserman I; Kremer I; Ehrlich R; Bahar I
    Br J Ophthalmol; 2014 Feb; 98(2):252-5. PubMed ID: 24276695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
    Kim MH; Koo TH; Sah WJ; Chung SM
    Ophthalmic Surg Lasers; 1998 Sep; 29(9):762-6. PubMed ID: 9760614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.
    Heiligenhaus A; Steinmetz B; Lapuente R; Krallmann P; Althaus C; Steinkamp WK; Dick B
    Br J Ophthalmol; 1998 Jul; 82(7):810-5. PubMed ID: 9924378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation].
    Xie L; Li S; Dong X; Cao J; Shi W; Guo P
    Zhonghua Yan Ke Za Zhi; 1998 Jul; 34(4):291-3. PubMed ID: 11877211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye.
    Tan DT; Chee SP; Lim L; Theng J; Van Ede M
    Ophthalmology; 2001 Dec; 108(12):2172-81. PubMed ID: 11733254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator for postvitrectomy fibrin formation.
    Jaffe GJ; Abrams GW; Williams GA; Han DP
    Ophthalmology; 1990 Feb; 97(2):184-9. PubMed ID: 2109297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.